MabVax reports Phase I data for cancer candidate MVT-1075

MabVax Therapeutics Holdings Inc. (NASDAQ:MBVX) reported interim data from three patients with CA19.9-positive malignancies in the first cohort

Read the full 189 word article

User Sign In